Scarica l'app Stockscreener
39.02
0.26%
-0.052
Precedente Chiudi:
$39.07
Aprire:
$39.12
Volume 24 ore:
50,116
Relative Volume:
0.43
Capitalizzazione di mercato:
$428.85M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+6.53%
1M Prestazione:
+56.51%
6M Prestazione:
+150.61%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$37.33
$39.13
Intervallo di 1 settimana:
$34.57
$39.40
Portata 52W:
$11.17
$40.50
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Nome
Palvella Therapeutics Inc
Settore
Industria
Telefono
(484) 253-1461
Indirizzo
125 STRAFFORD AVE, WAYNE
Confronta PVLA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
38.79 | 414.81M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
377.83 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.00 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.63 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
667.94 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
296.00 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-04-09 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-26 | Iniziato | Stifel | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-20 | Iniziato | Canaccord Genuity | Buy |
| 2025-02-05 | Iniziato | TD Cowen | Buy |
| 2024-12-26 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Iniziato | Robert W. Baird | Outperform |
| 2018-03-19 | Iniziato | Evercore ISI | Outperform |
| 2018-03-19 | Iniziato | Jefferies | Buy |
| 2018-01-16 | Reiterato | H.C. Wainwright | Buy |
| 2017-05-30 | Iniziato | Rodman & Renshaw | Buy |
| 2016-08-05 | Ripresa | ROTH Capital | Buy |
| 2015-08-12 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-07-27 | Iniziato | Oppenheimer | Outperform |
| 2015-07-22 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Palvella Therapeutics Inc Borsa (PVLA) Ultime notizie
Palvella Therapeutics Q2 2025 Earnings Call Scheduled for August 14 | PVLA Stock News - Stock Titan
Palvella Therapeutics CEO to Speak at Canaccord Genuity Growth Conference - MSN
Palvella Therapeutics Inc. stock volume spike explainedGrowth Watchlist for Long Term Positioning - Newser
Analysts Set Expectations for PVLA Q2 Earnings - Defense World
How to read the order book for Palvella Therapeutics Inc.AI Trade Signal Forecast with Chart Logic - Newser
How hedge fund analytics apply to Palvella Therapeutics Inc. stockCapital Growth Plan for New Investors - Newser
What makes Palvella Therapeutics Inc. stock price move sharplyHigh Yield Signals with Entry Timing - Newser
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
What institutional flow reveals about Palvella Therapeutics Inc.Predictive Analytics for Equity Growth Potential - Newser
Palvella Therapeutics (NASDAQ:PVLA) Rating Increased to Strong-Buy at Lifesci Capital - Defense World
Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
What indicators show strength in Palvella Therapeutics Inc.Weekly Outlook for Short Term Investors - Newser
Palvella Therapeutics Inc. stock trend forecastAI Intraday Market Movement Prediction Tool - Newser
Raymond James Initiates Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $54 - 富途牛牛
Raymond James initiates Palvella Therapeutics stock with Outperform rating By Investing.com - Investing.com Canada
Lifesci Capital Upgrades Palvella Therapeutics (NASDAQ:PVLA) to Strong-Buy - Defense World
Palvella Therapeutics CEO to Share Rare Disease Pipeline Updates at Major Growth Conference - Stock Titan
Palvella Therapeutics (NASDAQ:PVLA) Stock Rating Upgraded by Lifesci Capital - Defense World
Does Palvella Therapeutics Inc. fit your quant trading modelFree Real Trader Watchlist of Hot Stocks - Newser
Exit strategy if you’re trapped in Palvella Therapeutics Inc.Free Daily Smart Money Movement Monitor - Newser
Palvella Therapeutics Inc. Shows Risk Reward Favoring UpsideEntry Plan for Oversold Reversal Stocks Released - metal.it
Analysts Initiate Coverage on Akero Therapeutics, AeroVironment, Wave Life Sciences, Palvella Therapeutics, and WeRide Inc. - AInvest
This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Will Palvella Therapeutics Inc. stock split in the near futureFree Step-by-Step Stock Investment Guide - Newser
Real time scanner hits for Palvella Therapeutics Inc. explainedDaily Pattern Analysis with Return Forecast - Newser
Is it the right time to buy Palvella Therapeutics Inc. stockBuild wealth steadily with proven stock picks - Jammu Links News
Is Palvella Therapeutics Inc. stock overvalued or undervaluedAccess high-yield investment alerts now - Jammu Links News
What are analysts’ price targets for Palvella Therapeutics Inc. in the next 12 monthsUnlock steady growth with low-risk stocks - Jammu Links News
Will Palvella Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsReal-Time Setup Summary with ROI Focus - Newser
When is Palvella Therapeutics Inc. stock expected to show significant growthFree Trend-Following Techniques - Jammu Links News
Should I hold or sell Palvella Therapeutics Inc. stock in 2025Outstanding capital returns - Jammu Links News
How strong is Palvella Therapeutics Inc. company’s balance sheetUnlock real-time trading signals for gains - Jammu Links News
Is Palvella Therapeutics Inc. a growth stock or a value stockCapitalize on emerging investment opportunities - Jammu Links News
What catalysts could drive Palvella Therapeutics Inc. stock higher in 2025Maximize returns with timely market signals - Jammu Links News
What is the risk reward ratio of investing in Palvella Therapeutics Inc. stockMaximize portfolio growth with expert advice - Jammu Links News
What analysts say about Palvella Therapeutics Inc. stockBuild a winning investment strategy - Jammu Links News
What institutional investors are buying Palvella Therapeutics Inc. stockDiscover the next big stock winners - Jammu Links News
What are the latest earnings results for Palvella Therapeutics Inc.Unstoppable investment returns - Jammu Links News
Tools to assess Palvella Therapeutics Inc.’s risk profileRisk Aware Trading Ideas with Alert Levels - Newser
Palvella Therapeutics Inc Azioni (PVLA) Dati Finanziari
Non sono disponibili dati finanziari per Palvella Therapeutics Inc (PVLA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):